The BPC-157 + TB-500 Combination Protocol

The BPC-157 plus TB-500 combination protocol is the one way telos rx currently makes TB-500 available. It is worth understanding exactly what that means before starting an intake.

What the combination protocol is

The BPC-157 plus TB-500 combination protocol pairs two peptides, compounded BPC-157 and TB-500, into a single reviewed formulation. It is prepared by telos rx's partner compounding pharmacies as its own distinct product. It follows the same review process telos rx applies to its other compounded peptide offerings.

This is different from simply prescribing BPC-157 and TB-500 separately and letting a patient combine them. The combination is evaluated, formulated, and dispensed as one product from the outset, not assembled after the fact.

How it relates to standalone TB-500's regulatory status

TB-500 was classified as an FDA Category 2 bulk substance in late 2023. That classification restricts partner compounding pharmacies from preparing it as a standalone product. The combination protocol is a separately reviewed formulation, which is why it can be offered even though standalone TB-500 cannot.

This distinction is genuinely important to understand if you are researching TB-500 specifically. Interest in this combination product should be based on the combination itself, not treated as a workaround to obtain TB-500 alone through a different label.

Who typically looks into this protocol

People researching this combination are usually already familiar with BPC-157 and TB-500 individually. That familiarity often comes from recovery-focused research communities. They are curious whether a combined approach might suit their goals differently than either peptide alone.

A licensed provider is the right person to walk through whether that reasoning applies to your specific situation. Appropriateness depends on individual history and goals, rather than general assumptions about combination formulations working better simply because two peptides are involved.

How the intake process works

Like telos rx's other compounded peptide offerings, the combination protocol intake is asynchronous. You complete an online intake, and a licensed provider reviews your history. Approval is subject to that clinical review rather than automatic based on the request alone.

Anyone considering this protocol should also review the BPC-157 + TB-500 combination page for the most current details on what telos rx offers. Specifics can be updated as the program evolves, so it is worth checking before you start.

What the formulation does not claim

The combination protocol is described honestly as a formulation built around two studied peptides. It is not framed as a promised outcome. Much of the research behind BPC-157 and TB-500 remains at a preclinical stage, meaning laboratory and animal research rather than large controlled human trials.

telos rx does not present this combination as clinically proven to produce a specific result. A licensed provider can discuss what current research does and does not support, so your expectations are grounded in an honest picture rather than marketing language.

How it compares to other options at telos rx

If the combination protocol is not the right fit, telos rx also offers standalone compounded BPC-157. Some patients prefer this if their interest is specifically in that peptide, rather than the pairing with TB-500.

Patients interested in recovery-adjacent support more broadly sometimes also look at sermorelin, a growth-hormone-releasing peptide available today through telos rx. Reviewing all three options with a provider is a reasonable way to decide which, if any, fits your goals.

What to expect after starting

Once a provider approves the combination protocol, the prescription is routed to a partner compounding pharmacy for preparation. Shipping and handling follow the same process telos rx uses for its other compounded peptide products.

Ongoing questions about the protocol, including anything unclear about dosing or administration, should go through your care team rather than being pieced together from outside sources. That keeps guidance specific to your prescription rather than a general assumption about the peptides involved.

How the combination formulation was developed

Combination formulations like this one are not created casually. A compounding pharmacy and prescribing team typically review available research on each component and consider how the two peptides are proposed to interact. The result is structured to be reviewed as its own distinct product.

This process differs from simply prescribing two existing products side by side. It reflects a deliberate decision to treat the pairing as a single offering, subject to its own review rather than inheriting the regulatory status of either peptide individually.

That is part of why telos rx can describe the combination protocol as available while being equally clear that standalone TB-500 is not, without any contradiction between the two statements.

Setting realistic expectations before you start

Before beginning any compounded peptide protocol, it helps to have a realistic sense of what is and is not established. BPC-157 and TB-500 are both peptides with an active but still developing research base, not settled, fully proven treatments.

A licensed provider can walk through what current research does and does not show, and can answer specific questions about your own health history during intake. That conversation is a better foundation for a decision than general claims found on forums or unregulated seller pages.

Setting expectations honestly from the start also makes it easier to have a useful follow-up conversation with your care team later, since you will know what you were actually told going in.

Sourcing and quality behind the formulation

Compounded medication quality depends heavily on the pharmacy preparing it, not just the peptides involved. telos rx works only with partner compounding pharmacies that operate within current regulatory guidance and maintain their own quality processes.

This matters more, not less, for a combination formulation, since it depends on consistent preparation of two components together rather than one. Asking a provider how a combination product's quality is verified is a reasonable question, and one a legitimate pharmacy should be able to answer clearly.

Sourcing quality is a separate question from clinical appropriateness, but both matter. A well-sourced product prescribed for the wrong reasons is not a good outcome, and neither is a well-matched prescription filled by an unreliable pharmacy. telos rx's LegitScript certification is one signal of that reliability, though it is worth asking direct questions of any provider you work with.

Who should not consider this protocol

Like any compounded medication, the combination protocol is not automatically appropriate for everyone who is curious about it. A licensed provider reviews individual health history specifically to catch situations where a protocol would not be a good fit.

This is one reason telos rx's intake process is not a simple checkout. It is a clinical review designed to catch mismatches between a product and a patient before anything is prescribed. Being declined is not a failure. It is the review process working as intended.

If you have questions about your own eligibility before starting intake, raising them directly with the care team is more useful than guessing based on general information. Every situation is reviewed individually, and a general article cannot substitute for that specific review.

Where to read more, from primary sources

For general background on how the FDA approaches compounding oversight, see the FDA's compounding questions and answers page. For published research involving thymosin beta-4, the natural protein TB-500 is derived from, see this PubMed search of the current literature. Reading primary sources directly is a better habit than relying on secondhand summaries, especially for a peptide whose regulatory status and research base are both still evolving.

Frequently Asked Questions

What exactly is in the BPC-157 plus TB-500 combination protocol?

It pairs compounded BPC-157 with TB-500 in a single formulation, prepared by telos rx's partner compounding pharmacies as a distinct, reviewed product rather than two separate prescriptions.

Is this the same as getting TB-500 alone?

No. Standalone TB-500 is not currently compounded due to its FDA Category 2 bulk substance status. The combination protocol is a separately reviewed formulation, not standalone TB-500 dispensed independently under a different name.

How do I start the intake for this protocol?

You complete telos rx's standard online intake, and a licensed provider reviews your history before any approval. The process mirrors telos rx's other compounded peptide offerings closely.

Can I request BPC-157 and TB-500 as two separate prescriptions instead?

TB-500 is not available as a standalone prescription due to its current regulatory classification. It is only offered through the reviewed combination formulation described on this page, not as an individually dispensed product.

Is the combination protocol right for everyone interested in these peptides?

Not necessarily. Suitability depends on your individual history and goals, which is why a licensed provider reviews each intake rather than approving requests automatically without clinical review of your specific situation.

Where can I find the most current details on this protocol?

The BPC-157 plus TB-500 combination page on telosrx.com is the most current source. Program details can be updated over time as regulatory status evolves and as telos rx's partner pharmacies refine the formulation.

telos rx is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations by partner compounding pharmacies. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.

Questions about the BPC-157 + TB-500 combination protocol? Message the telos rx care team or read more on the BPC-157 + TB-500 combination page.